Patent intelligence · US
US 11318098
Liposomal apparatus and manufacturing methods
Liposomal apparatus and manufacturing methods
Patent details — US 11318098
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 3, 2022
- Expiration
- Apr 28, 2042
- Applicant
- ARBUTUS BIOPHARMA CORPORATION
- Claims
- 30
- CPC classes
- A61K, A61K31/7084, A61K31/7088, A61K47/10
Quick answer
US 11318098 (Liposomal apparatus and manufacturing methods) is held by ARBUTUS BIOPHARMA CORPORATION. Status: granted. Granted May 3, 2022. Expires Apr 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ARBUTUS BIOPHARMA CORPORATION
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/7084, A61K31/7088, A61K47/10, A61K47/24, A61K47/44
More from ARBUTUS BIOPHARMA CORPORATION
Related pharmaceutical patents in our USPTO index.
-
US 12357705
Negatively charged peg-lipid conjugates
granted -
US 12350383
Cationic lipids containing silicon
granted -
US 12251470
Lipid nanoparticle formulations
granted -
US 12129467
Non-liposomal systems for nucleic acid delivery
granted -
US 12083118
Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
granted -
US 12043833
Targeted compositions
granted -
US 12042541
Lipids and compositions for the delivery of therapeutics
granted -
US 12023383
Lipid compositions
granted
Frequently asked questions
What is US patent 11318098?
US 11318098 (Liposomal apparatus and manufacturing methods) is held by ARBUTUS BIOPHARMA CORPORATION. Status: granted. Granted May 3, 2022. Expires Apr 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11318098?
ARBUTUS BIOPHARMA CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 56 pharmaceutical patents for this assignee.
When does US 11318098 expire?
Our index shows an expiration date of Apr 28, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.